Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Status: Recruiting
DFCI Protocol ID: 18-141

This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to standard therapy.

Conducting Institutions:

Children's Hospital Boston, Dana-Farber Cancer Institute

Overall PI:

Steven Dubois MD, Dana Farber Cancer Institute

Site-responsible Investigators:


Dana-Farber Cancer Institute: Childrens Hospital Pediatric Clinical Translation Investigation Program CTIP,

Eligibility Criteria

Inclusion Criteria:

  -  Signed informed consent form by patients and/or patients' parents/legal guardians and
     age appropriate assent form by the patients obtained before any study specific

  -  Male or female patients from 6 months to ≤ 21 years old at the time of study

  -  Confirmation of diagnosis:

       -  Phase I: Patients must have histologic verification of a solid tumor or lymphoma
  malignancy at diagnosis for which there is no standard curative anti-cancer
  treatment or treatment is no longer effective and must have received ≥ 1 prior
  line of therapy.

       -  Phase II: patients must have histologically verified tumor at initial diagnosis
  and radiologically or histologically confirmed status at inclusion as indicated
  in the following: neuroblastoma, osteosarcoma, rhabdomyosarcoma or Ewing sarcoma.

       -  Patients with solid tumors must have measurable or evaluable (for neuroblastoma
  and Ewing sarcoma) disease. Tumor assessment will be done via computed tomography
  (CT), magnetic resonance imaging (MRI) or positron emission tomography-computed
  tomography (PET-CT). Tumor lesions situated in a previously irradiated area, or
  in an area subjected to other loco-regional therapy, may be considered measurable
  if there has been demonstrated progression in the lesion. Bone scans (if
  clinically indicated) should be obtained within ≤ 4 weeks prior to the start of

  -  Performance level: Lansky ≥ 50% for patients ≤ 16 years of age and Karnofsky ≥ 50% for
     patients > 16 years of age.

  -  Adequate bone marrow, renal and liver function.

Exclusion Criteria:

  -  Active or uncontrolled infection (National Cancer Institute (NCI)-CTCAE Grade ≥ 2).

  -  History or concurrent condition of interstitial lung disease of any severity and/or
     severely impaired lung function (as judged by the investigator).

  -  Diabetes mellitus.

  -  Uncontrolled arterial hypertension despite optimal medical management (per
     institutional guidelines).

  -  Patients with central nervous system (CNS) malignancies.

Know Your Options

Not sure which clinical trials might be right for your child? Email our clinical trials team at
We can help you navigate your options.

Get Clinical Trial Updates


Stay informed about Dana-Farber/Boston Children's research efforts, including information on new and current clinical trials. Sign up to receive our email newsletter Advances in Pediatric Hematology/Oncology.